| Literature DB >> 34238687 |
Nir Erdinest1, Naomi London2, Nadav Levinger3, Itay Lavy1, Eran Pras4, Yair Morad4.
Abstract
The COVID-19 pandemic of 2020 and its' accompanied lockdowns impacted the entire globe in ways the world is only beginning to comprehend. In Israel, children age 9-15 had not been in a frontal classroom and been socially restricted from March 2020 till March 2021. Fourteen of these children that had been under myopia control treatment which had been effective prior to the pandemic were included in this retrospective study to learn if their myopia continued to stay under control, or if the unique environmental modifications affected their progression. The results showed that average increase in spherical equivalent refraction and axial length, measured with optical biometer OA-2000 (Tomey GmbH, Nagoya, Japan), during the year of lockdowns was -0.73 ± 0.46D/0.46 ± 0.31 mm respectively, while the average increase in the year prior was -0.33 ± 0.27D/0.24 ± 0.21 mm. Though several articles have indicated the pandemic environment has influenced myopia progression in children, this communication indicates a possible significant impact of the environment on myopia increase even in individuals under effective atropine treatment. These children's' progression suggests practitioners consider and address multiple aspects simultaneously when attempting myopia control.Entities:
Keywords: Home-education; Lockdowns; Myopia control; Myopia progression
Mesh:
Substances:
Year: 2021 PMID: 34238687 PMCID: PMC9278875 DOI: 10.1016/j.clae.2021.101475
Source DB: PubMed Journal: Cont Lens Anterior Eye ISSN: 1367-0484 Impact factor: 3.946
Demographic data and binocular status at the beginning of treatment in March 2019, the refractive and axial length measurements of each child and the increase during year one (March 2019–March 2020) and year two, a year of lockdown and social distancing (March 2020–March 2021).
| Age March 2019 | Binocular March 2019 | SE 2019 | AL 2019 | SE 2020 | AL 2020 | March 2019–March2020 | SER 2021 | AL 2021 | March 2020–March 2021 | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # | M/F | Far | Near | L | R | L | R | L | R | L | R | ΔAL (L) | ΔAL (R) | ΔSER (L) | ΔSER (R) | L | R | L | R | ΔAL (L) | ΔAL (R) | ΔSER (L) | ΔSER (R) | |
| 1 | M | 9 | Ortho | Ortho | 3 | 4 | 23.22 | 23.2 | 3.25 | 4.5 | 23.41 | 23.59 | 0.19 | 0.38 | 0.25 | 0.5 | 4.37 | 5.5 | 24.11 | 24.21 | 0.7 | 0.63 | 1.125 | 1 |
| 2 | F | 9.5 | Ortho | Ortho | 2.75 | 3.25 | 2.75 | 3.25 | 23.87 | 24.18 | 0 | 0 | 3.75 | 3.75 | 24.49 | 24.49 | 0.63 | 0.31 | 1 | 0.5 | ||||
| 3 | F | 14 | Ortho | Ortho | 2.75 | 4.25 | 25.54 | 3 | 4.25 | 25.73 | 25.08 | 0.19 | 0.25 | 0 | 4.5 | 5.6 | 26.67 | 25.92 | 0.94 | 0.84 | 1.5 | 1.35 | ||
| 4 | F | 10 | 20XP | 8XP | 7 | 5.25 | 25.07 | 24.42 | 6.75 | 5.75 | 24.87 | 24.8 | −0.19 | 0.38 | −0.25 | 0.5 | 8.25 | 6 | 25.81 | 24.96 | 0.94 | 0.16 | 1.5 | 0.25 |
| 5 | F | 15 | Ortho | Ortho | 7.75 | 7.5 | 25.95 | 25.45 | 8 | 8.25 | 26.14 | 26.14 | 0.19 | 0.68 | 0.25 | 0.75 | 8 | 8.25 | 26.22 | 26.45 | 0.08 | 0.31 | 0 | 0 |
| 6 | M | 9 | Ortho | Ortho | 6.62 | 6.62 | 26.09 | 25.5 | 7.25 | 7 | 26.58 | 25.82 | 0.48 | 0.31 | 0.62 | 0.37 | 7.75 | 8.5 | 26.84 | 27.07 | 0.26 | 1.25 | 0.5 | 1.5 |
| 7 | M | 9 | Ortho | ET8 | 1.25 | 1.5 | 23.15 | 23.17 | 1.75 | 2.25 | 23.54 | 23.75 | 0.38 | 0.58 | 0.5 | 0.75 | 2.75 | 3.1 | 24.16 | 24.28 | 0.63 | 0.53 | 1 | 0.85 |
| 8 | F | 9.5 | Ortho | Ortho | 2.75 | 2 | 23.76 | 23.9 | 3.25 | 2.25 | 24.15 | 24.09 | 0.38 | 0.19 | 0.5 | 0.25 | 4 | 2.75 | 24.52 | 24.37 | 0.38 | 0.28 | 0.75 | 0.5 |
| 9 | M | 9 | Ortho | Ortho | 4.5 | 4.5 | 25.99 | 26.05 | 5.25 | 5.12 | 26.57 | 26.53 | 0.58 | 0.48 | 0.75 | 0.62 | 5.6 | 5.5 | 26.76 | 26.74 | 0.19 | 0.21 | 0.35 | 0.37 |
| 10 | M | 11.5 | Ortho | 4EP | 2.75 | 2.75 | 2.75 | 2.75 | 24.76 | 24.57 | 0 | 0 | 3.75 | 3.75 | 25.38 | 25.19 | 0.63 | 0.63 | 1 | 1 | ||||
| 11 | M | 9 | Ortho | Ortho | 3.25 | 3 | 22.8 | 22.65 | 3.75 | 3.75 | 23.19 | 23.02 | 0.38 | 0.37 | 0.5 | 0.75 | 4.1 | 4.12 | 23.36 | 23.21 | 0.18 | 0.19 | 0.35 | 0.37 |
| 12 | M | 9 | Ortho | Ortho | 0.75 | 0.75 | 23.14 | 23.41 | 1 | 1 | 23.3 | 23.54 | 0.16 | 0.13 | 0.25 | 0.25 | 2.25 | 1.5 | 24.08 | 23.85 | 0.78 | 0.31 | 1.25 | 0.5 |
| 13 | M | 10.5 | Ortho | Ortho | 2.75 | 3.5 | 25.19 | 25.53 | 3 | 3.75 | 25.34 | 25.67 | 0.15 | 0.14 | 0.25 | 0.25 | 3.5 | 4.25 | 25.59 | 25.92 | 0.25 | 0.25 | 0.5 | 0.5 |
| 14 | M | 13 | Ortho | Ortho | 8.5 | 8.25 | 25.46 | 25.34 | 8.75 | 8.5 | 25.6 | 25.49 | 0.14 | 0.15 | 0.25 | 0.25 | 8.75 | 9.6 | 25.65 | 26.18 | 0.06 | 0.69 | 0 | 1.1 |
| AVG ± SD | 10.50 ± 2.07 | 4.03 ± 2.45 | 4.08 ± 2.20 | 24.61 ± 1.29 | 24.42 ± 1.20 | 4.32 ± 2.44 | 4.46 ± 2.26 | 24.79 ± 1.23 | 24.73 ± 1.09 | 0.25 ± 0.20 | 0.34 ± 0.18 | 0.29 ± 0.27 | 0.38 ± 0.28 | 5.09 ± 2.18 | 5.16 ± 2.33 | 25.26 ± 1.14 | 25.20 ± 1.19 | 0.47 ± 0.31 | 0.47 ± 0.31 | 0.77 ± 0.50 | 0.70 ± 0.44 | |||
| R+L AVG ± SD | 4.05 ± 2.29 | 24.52 ± 1.22 | 4.46 ± 2.26 | 24.76 ± 1.14 | 0.29 ± 0.2 | 0.33 ± 0.27 | 5.13 ± 2.22 | 25.23 ± 1.14 | 0.47 ± 0.30 | 0.74 ± 0.46 | ||||||||||||||
Abbreviations: M/F: male/female, XP: exophoria, ET: esotropia, EP: esophoria, SER: spherical equivalent refraction (diopter), AL: axial length (mm).